Stock Movers: PepsiCo, United Airlines, Lucid
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
SS&C Technologies to Acquire Calastone
WINDSOR, Conn., July 21, 2025--(BUSINESS WIRE)--SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced a definitive agreement to acquire Calastone, the largest global funds network and leading provider of technology solutions to the wealth and asset management industries, from global investment firm Carlyle. The purchase price is approximately £766 million (approximately US $1.03 billion), subject to certain adjustments. Headquartered in London, Calastone operates the largest global funds network, connecting more than 4,500 of the world's leading financial organizations across 57 markets. The acquisition is expected to close in Q4 2025, subject to regulatory approvals. SS&C expects the acquisition to be accretive within 12 months and plans to fund the purchase with a combination of debt and cash on hand. Calastone's more than 250 staffers in London, Luxembourg, Hong Kong, Taipei, Singapore, New York and Sydney are expected to join SS&C Global Investor & Distribution Solutions, reporting to General Manager Nick Wright. "We're excited to welcome Julien, the Calastone team and their valued clients to SS&C," said Bill Stone, Chairman and CEO of SS&C Technologies. "Together, we will create a more connected, automated, and intelligent global fund ecosystem — reducing complexity, enhancing client experience, and shaping the future of distribution and investment operations." The acquisition of Calastone reinforces SS&C's commitment to transforming investment operations and bolsters SS&C's ongoing geographic expansion. Calastone's global network and technology solutions complement SS&C's leadership in fund administration, transfer agency services, AI and intelligent automation. By combining capabilities, the two companies will deliver a unified, real-time operating platform to reduce cost, complexity, and operational risk across the global fund ecosystem as well as shaping distribution. This strategic alignment enables enhanced distribution, investor servicing, and operational scalability — empowering asset and wealth managers to innovate, diversify products, and deliver better outcomes for investors worldwide. "We are pleased to be combining forces with SS&C in our joint mission to build the most comprehensive, intelligent and connected wealth and asset management ecosystem," said Julien Hammerson, CEO of Calastone. "SS&C's global scale and deep expertise across fund services and technology will enable us to accelerate innovation and deliver new digital capabilities to the market. We look forward to working together to deliver transformational services to asset and wealth managers and drive growth." Fernando Chueca, Managing Director on the Carlyle Europe Technology Partners investment advisory team, said: "We are pleased to have supported Calastone through such a transformational period of growth for the business. Its well-established technology network represents a differentiated, automated offering and we believe the business is well-positioned to build upon its market position and business momentum. We are confident that SS&C is the right partner to continue Calastone's success, and we look forward to watching the company thrive in its next phase." SS&C was advised by Davis Polk & Wardwell LLP. Barclays served as exclusive financial advisor to Calastone and Linklaters and Mishcon De Reya served as legal advisors to Calastone in connection with the transaction. About Calastone Calastone is the largest global funds network, connecting the world's leading financial organisations. Calastone's mission is to reduce complexity, risk and costs, enabling the industry to deliver greater value to investors. 4,500 clients in 57 countries and territories benefit from Calastone's services, processing over £250 billion of investment value each month. Calastone is headquartered in London and has offices in Luxembourg, Hong Kong, Taipei, Singapore, New York and Sydney. About SS&C Technologies SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 22,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale, and technology. About Carlyle Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group. Additional information about SS&C (Nasdaq:SSNC) is available at SS&C on X, LinkedIn and Facebook. View source version on Contacts Brian SchellChief Financial OfficerSS&C TechnologiesTel: +1-816-642-0915E-mail: InvestorRelations@ Justine StoneInvestor RelationsSS&C TechnologiesTel: +1- 212-367-4705E-mail: InvestorRelations@ Media Contacts Sam GentileTel : +1-646-818-9195Email : pro-SSC@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Cell‑Based Assays Report 2025: Key Market Drivers, Tech Trends & Competitive Landscape to 2030
The global cell-based assays market is set to grow from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, marking a CAGR of 9.1%. This surge is fueled by the rising demand in drug discovery and increased R&D investments by the pharmaceutical and biotech industries. The prevalence of cancer is boosting the need for advanced therapies, while the growth of cell-based assays applications in chronic diseases and personalized medicine further propels market expansion. In 2024, the drug discovery and flow cytometry segments dominated the market. The US, with its strong healthcare infrastructure and biopharmaceutical industry, led the global market. Key companies in this sector include BD, Thermo Fisher Scientific, and Merck KGaA. Cell Based Assays Market Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030" has been added to global cell-based assays market is anticipated to expand from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.1%. This growth is fueled by escalating demand in drug discovery and the increasing need for sophisticated therapies, particularly in oncology. An uptick in research and development investments from pharmaceutical and biotechnology firms is another catalyst propelling market expansion. Drug Discovery's Dominance in Applications Within the applications segment, drug discovery is poised to retain its prominence through 2024. It encompasses subcategories such as toxicity, pharmacokinetics, and pharmacodynamics studies. The segment's ascendancy is largely attributed to the burgeoning incidence of cancer, which heightens demand for novel therapies. Additionally, robust investments and the emergence of contract research organizations are significantly advancing drug discovery efforts. Flow Cytometry Leads Technological Innovations In 2024, the flow cytometry segment emerged as a leader within the technology category, driven by its pivotal role in providing comprehensive cell-based assay measurements. Enhanced adoption of cutting-edge technologies for cell analysis continues to bolster this sector, ensuring its sustained growth trajectory. Regional Insights and U.S. Market Leadership The U.S. held a commanding position in the North American market in 2024, attributed to its stature as the largest biopharmaceutical hub globally. This leadership is strengthened by significant research investments and a robust healthcare framework. The emphasis on developing advanced cell-based therapies is a key driver in response to rising cancer cases. Notable Market Players: BD (US) Thermo Fisher Scientific Inc. (US) Danaher Corporation (US) Merck KGaA (Germany) Agilent Technologies, Inc. (US) Lonza (Switzerland) Charles River Laboratories (US) Bio-Rad Laboratories, Inc. (US) REVVITY (US) Sartorius AG (Germany) And others Research Coverage and Market Insights: The report categorizes the cell-based assays market based on offerings, technology, applications, end users, and regions. It elucidates major drivers, restraints, opportunities, and challenges influencing market dynamics. Additionally, a comprehensive analysis of key industry players, including product launches, collaborations, and acquisitions, sheds light on the competitive landscape. Key Insights for Stakeholders: Drivers such as increasing demand for drug discovery, rising prevalence of cancer, and heightened R&D investments. Constraints involving high costs and licensing restrictions. Opportunities in chronic diseases and personalized medicine sectors. Competitive assessment of major players highlighting their strategies and market positioning. Key Attributes: Report Attribute Details No. of Pages 449 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $17.84 Billion Forecasted Market Value (USD) by 2030 $27.55 Billion Compound Annual Growth Rate 9.1% Regions Covered Global Key Topics Covered: Market Dynamics Drivers Growing Demand For Drug Discovery & Development and Increasing Preference For Cell-Based Assays in Drug Discovery Government Support and Funding For Cell-Based Research Growing Efforts To Curtail Animal-Based Studies Rising Prevalence of Cancer Alliances To Accelerate Innovations in Drug Discovery Restraints High Cost of Instruments and Restrictions Imposed by Product End-User Licenses For Reagents Lack of Standardization of Protocols Used in Cell-Based Assays Opportunities Growing Applications of Cell-Based Assays in Chronic Diseases and Personalized Medicine Growth Opportunities in Emerging Economies Rising Adoption of AI in Drug Discovery and Cell Analysis Challenges Complexities in Assay Designs Shortage of Skilled Professionals Company Profiles Danaher Thermo Fisher Scientific Inc. Merck Kgaa BD Agilent Technologies, Inc. Lonza Eurofins Scientific Charles River Laboratories Bio-Rad Laboratories, Inc. Revvity Sartorius Ag Corning Incorporated Promega Corporation Cell Signaling Technology, Inc. Enzo Biochem Inc. Carna Biosciences, Inc. Intertek Group Plc Bico Cell Biolabs, Inc. Reaction Biology AAT Bioquest, Inc. Pestka Biomedical Laboratories, Inc. Neuromics BPS Bioscience, Inc. Bellbrook Labs Profacgen Bmg Labtech Gmbh Hanugen Therapeutics Altogen Labs Bioagilytix Labs For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Based Assays Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNET
23 minutes ago
- CNET
Refi Rates Ride High: Current Refinance Rates on July 21, 2025
For the vast majority of homeowners, there's currently little financial incentive to refinance their mortgages. So far in 2025, average mortgage rates have remained elevated, consistently hovering between 6.5% and 7% due to ongoing economic uncertainty. "If rates fall below 6%, we could see a big jump in refinance activity," said Jeb Smith, licensed real estate agent and member of CNET Money's expert review board. Yet economists and housing market experts don't predict a dramatic drop-off in rates in the immediate future. Mortgage refinance rates fluctuate daily based on a range of economic and political factors. For more insights on where rates might be headed, check out our weekly mortgage rate forecast. When mortgage rates start to fall, be ready to take advantage. Experts recommend shopping around and comparing multiple offers to get the lowest rate. Enter your information here to get a custom quote from one of CNET's partner lenders. About these rates: Bankrate's tool features rates from partner lenders that you can use when comparing multiple mortgage rates. Refinance rate news At the start of 2025, many expected inflation to keep cooling down and the Federal Reserve to cut interest rates, which would have gradually lowered mortgage refinance rates. However, after cutting interest rates three times last year, the Fed has held rates steady in 2025 to observe how President Trump's policies on trade, immigration and government spending will affect the economy. The central bank is expected to resume cutting rates as early as September, but this will not immediately result in lower mortgage rates. While adjustments to its benchmark interest rate influence the direction of borrowing rates across the economy, the Fed doesn't directly control the mortgage market. As of now, the Fed is expected to make two 0.25% rate reductions this year. If inflation increases due to tariffs, policymakers may hold off on easing borrowing costs until later, which would keep upward pressure on mortgage refinance rates. What to know about 2025 refinance rate expectations Most housing forecasts still call for a modest decline in mortgage rates, with average 30-year fixed rates expected to end the year around below 6.5%. For refinancing to become significantly more affordable, though, we need to see multiple interest rate cuts and weaker economic data. Overall, it's unlikely we'll see another refinancing boom like the one in 2020-21 when mortgage rates were exceptionally low around 3%. Nevertheless, refinancing might be beneficial for other reasons, like changing the type of home loan, term length or taking someone off the mortgage. What to know about refinancing When you refinance your mortgage, you take out another home loan that pays off your initial mortgage. With a traditional refinance, your new home loan will have a different term and/or interest rate. With a cash-out refinance, you'll tap into your equity with a new loan that's bigger than your existing mortgage balance, allowing you to pocket the difference in cash. Refinancing can be a great financial move if you score a low rate or can pay off your home loan in less time, but consider whether it's the right choice for you. Reducing your interest rate by 1% or more is an incentive to refinance, allowing you to cut your monthly payment significantly. But refinancing your mortgage isn't free. Since you're taking out a whole new home loan, you'll need to pay another set of closing costs. If you fall into that pool of homeowners who purchased property when rates were high, consider reaching out to your lender and running the numbers to see whether a mortgage refinance makes sense for your budget, said Logan Mohtashami, lead analyst at HousingWire. How to choose the right refinance type and term The rates advertised online often require specific conditions for eligibility. Your personal interest rate will be influenced by market conditions as well as your specific credit history, financial profile and application. Having a high credit score, a low credit utilization ratio and a history of consistent and on-time payments will generally help you get the best interest rates. 30-year fixed-rate refinance For 30-year fixed refinances, the average rate is currently at 6.87%, an increase of 6 basis points from what we saw one week ago. (A basis point is equivalent to 0.01%.) A 30-year fixed refinance will typically have lower monthly payments than a 15-year or 10-year refinance, but it will take you longer to pay off and typically cost you more in interest over the long term. 15-year fixed-rate refinance For 15-year fixed refinances, the average rate is currently at 6.21%, an increase of 10 basis points compared to one week ago. Though a 15-year fixed refinance will most likely raise your monthly payment compared to a 30-year loan, you'll save more money over time because you're paying off your loan quicker. Also, 15-year refinance rates are typically lower than 30-year refinance rates, which will help you save more in the long run. 10-year fixed-rate refinance The average rate for a 10-year fixed refinance loan is currently 6.38%, an increase of 29 basis points over last week. A 10-year refinance typically has the lowest interest rate but the highest monthly payment of all refinance terms. A 10-year refinance can help you pay off your house much quicker and save on interest, but make sure you can afford the steeper monthly payment. To get the best refinance rates, make your application as strong as possible by getting your finances in order, using credit responsibly and monitoring your credit regularly. And don't forget to speak with multiple lenders and shop around. Does refinancing make sense? Homeowners usually refinance to save money, but there are other reasons to do so. Here are the most common reasons homeowners refinance: To get a lower interest rate: If you can secure a rate that's at least 1% lower than the one on your current mortgage, it could make sense to refinance. If you can secure a rate that's at least 1% lower than the one on your current mortgage, it could make sense to refinance. To switch the type of mortgage: If you have an adjustable-rate mortgage and want greater security, you could refinance to a fixed-rate mortgage. If you have an adjustable-rate mortgage and want greater security, you could refinance to a fixed-rate mortgage. To eliminate mortgage insurance: If you have an FHA loan that requires mortgage insurance, you can refinance to a conventional loan once you have 20% equity. If you have an FHA loan that requires mortgage insurance, you can refinance to a conventional loan once you have 20% equity. To change the length of a loan term: Refinancing to a longer loan term could lower your monthly payment. Refinancing to a shorter term will save you interest in the long run. Refinancing to a longer loan term could lower your monthly payment. Refinancing to a shorter term will save you interest in the long run. To tap into your equity through a cash-out refinance: If you replace your mortgage with a larger loan, you can receive the difference in cash to cover a large expense. If you replace your mortgage with a larger loan, you can receive the difference in cash to cover a large expense. To take someone off the mortgage: In case of divorce, you can apply for a new home loan in just your name and use the funds to pay off your existing mortgage.
